ClinicalTrials.gg
Active, not recruitingNCT07947108Updated Nov 18, 2026

A Clinical Trial to Evaluate the Effects of a Supplement on Urinary Symptoms

An interventional study of Product Intervention in Urinary Tract Infection, Recurrent Urinary Tract Infection and Urinary Symptoms, sponsored by Good Kitty Co. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Good Kitty Co · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2026, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 274 studies in Urinary Tract Infections with a site in United States — 43 open to participants now, 56 under way, 2 of them phase 3. Urinary Tract Infections · United States.

Enrollment
151st of 224
44 · median 100
Started
2026
with 19 others
No phase
94 of 274
19 open now
Primary completion
2026-12
later than 12 of 55 live
Registered
274th of 274
by date

Among the 274 studies in Urinary Tract Infections with a site in United States, this one is the 151st largest by enrollment of the 224 interventional ones that give a count, is one of 20 that started in 2026, is one of 94 with no phase, reaches primary completion later than 12 of the 55 other live ones, and was the 274th registered.

Urinary Tract Infections

807 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

43 of the 274 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (28%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 274 studies in Urinary Tract Infections with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the effects of the UTI Biome Shield capsule on urinary symptoms in sexually active women aged 18-45 who experience recurrent symptoms associated with urinary tract infections (UTIs). The trial is a single-arm, unblinded, virtual study conducted over six months, in which all 44 enrolled participants will use the test product daily.

Participants will complete questionnaires at Baseline and at the end of Months 1 through 6. The primary objective is to examine the product's effects on urinary symptoms, while secondary objectives assess participants' perceptions of the product's effects, including reduced recurrence of UTI-associated symptoms in sexually active women and reduced recurrence of symptoms after sex.

03

Conditions studied

  • Urinary Tract Infection
  • Recurrent Urinary Tract Infection
  • Urinary Symptoms
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be female
  • Be aged 18-45
  • Is sexually active and engages in sexual activity at least twice per week
  • Has had either two or more episodes with symptoms associated with UTIs in the past six months (including frequent and urgent urination, a burning sensation during urination, and cloudy urine), or three or more episodes with symptoms associated with UTIs in the past 12 months (including frequent and urgent urination, a burning sensation during urination, and cloudy urine)
  • Self-reports recurrent symptoms associated with UTIs specifically after sex (including frequent and urgent urination, a burning sensation during urination, and cloudy urine) requiring administration of antibiotics, and self-reports sex as a predominant trigger (UTI onset typically 24-48 hours after intercourse)
  • below 30 kg/m²
  • Generally healthy - does not live with any uncontrolled chronic disease
  • If taking oral over-the-counter supplements or herbal remedies targeted at symptoms associated with UTIs, must have been consistently taking these for at least 3 months before starting the study and be willing to maintain this routine for the study duration
  • Willing to keep all elements of their female hygiene routine the same for the duration of the study
  • Willing to maintain the same diet and exercise regimen consistently throughout the study duration
  • Resides in the United States

Exclusion criteria

Exclusion Criteria:

  • Currently taking the anticoagulant warfarin
  • Currently taking antibiotics or who will be during the trial period (not including those prescribed for an acute urinary tract infection)
  • Currently taking prophylactic antibiotics for urinary tract infections, either taken daily or taken before sex
  • Diagnosed with a sexually transmitted disease within the last three months (e.g., chlamydia, trichomoniasis, gonorrhea, genital herpes)
  • History of interstitial cystitis/bladder pain syndrome, overactive bladder, pelvic floor dysfunction, or other conditions that can mimic UTI symptoms
  • Pre-existing chronic conditions that would prevent adherence to the protocol, including oncological and psychiatric disorders
  • Planned invasive medical procedures during the study period
  • Planning to introduce any products or new forms of prescription medication or supplements that target symptoms associated with UTI for the study duration
  • Any allergies or sensitivities to any of the study product ingredients
  • Any woman who is pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
  • Unwilling to follow the study protocol
  • Has stopped or started using hormonal in the past month
  • History of substance abuse
  • Currently partaking in another research study or who will be partaking in any other research study at any point during this study's duration
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Product Arm

    Dietary Supplement: Product Intervention

Interventions

  • Dietary supplementProduct Intervention

    All participants will be using the test product as directed. Participants who are sexually active in the morning will take the UTI Biome Shield capsule once daily in the afternoon after food. Participants who are sexually active in the evening will take the UTI Biome Shield capsule once daily in the morning after food. Participants will also take three capsules before sex.

06

What researchers measure

Primary outcomes

  1. Change in Urinary Symptoms

    Changes in urinary symptoms assessed via self-reported questionnaire

    Time frame: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6

Secondary outcomes

  1. Recurrence of Symptoms Associated with Urinary Tract Infections in Sexually Active Women

    Participants' self-reported perceptions of recurrence of UTI-associated symptoms (frequent and urgent urination, burning sensation during urination, cloudy urine) in sexually active women, assessed via questionnaire

    Time frame: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6

  2. Recurrence of Symptoms Associated with Urinary Tract Infections After Sex

    Participants' self-reported perceptions of recurrence of UTI-associated symptoms after sexual activity, assessed via questionnaire

    Time frame: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 154 interventional studies with no phase under Urinary Tract Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 37. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Apr 17, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07947108
Lead sponsor
Good Kitty Co
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Apr 17, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion